Aravax appoints Louise Peacock as Chief Regulatory and Quality Officer
Melbourne, Australia and Oxford, UK – 2 June 2025- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer, based at the Company’s Oxford, UK site.
With more than 35 years in the pharmaceutical industry, Louise brings extensive and highly relevant experience to Aravax, having previously made key contributions to the approval of Palforzia® - the first and only FDA-approved oral immunotherapy (OIT) to treat peanut allergy.
Louise has held prior roles as Chief Regulatory Affairs and Quality Officer at Vaderis Therapeutics AG and Alladapt Immunotherapeutics and was Head of Pharma R&D at Nestle Health Science/Aimmune Therapeutics (acquired by Nestle Health Science in 2020) where she had broad responsibilities for global regulatory affairs across pharma products in food allergy, gastrointestinal and metabolic disorders. Whilst at Aimmune, Louise was responsible for activities supporting the development and marketing approvals for Palforzia® in the US, EU, UK and Switzerland. Louise’s early career included senior positions at Abbott Laboratories, Auxilium Pharmaceuticals, Intermune and Circassia. Louise received her BSc (Hons) Pharmacology from Kings College, London and her LLB (Hons) from the University of West London.
Louise Peacock, Chief Regulatory and Quality Officer of Aravax said:
Despite recent advances, food allergy remains an ever-growing and life-threatening problem around the world and there is a critical need for better therapies. Having followed Aravax’s developments, I am convinced that PVX108 has the potential to be a life-changing alternative for patients with peanut allergy. I look forward to joining what is a world-class team and to bringing my experience to bear on the rapid further development of PVX108 and other products.
Dr Pascal Hickey, CEO of Aravax, said:
Louise’s experience in regulatory affairs in the field of food allergy is unique. It spans all the major regulatory bodies and multiple programs including the successful approval of Palforzia®. We are enormously excited that she is joining the Aravax team.
